S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
NASDAQ:APTO

Aptose Biosciences - APTO Stock Forecast, Price & News

$0.85
-0.01 (-1.16%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.85
$0.87
50-Day Range
$0.71
$0.92
52-Week Range
$0.71
$3.13
Volume
150,889 shs
Average Volume
213,426 shs
Market Capitalization
$78.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.67

Aptose Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
914.1% Upside
$8.67 Price Target
Short Interest
Healthy
0.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.16mentions of Aptose Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$9,700 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.48) to ($0.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

583rd out of 1,122 stocks

Biological Products, Except Diagnostic Industry

84th out of 178 stocks

APTO stock logo

About Aptose Biosciences (NASDAQ:APTO) Stock

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Aptose Biosciences Stock Performance

Shares of APTO Stock opened at $0.85 on Thursday. The company has a market capitalization of $78.87 million, a price-to-earnings ratio of -1.36 and a beta of 1.52. The company has a 50-day simple moving average of $0.82 and a 200 day simple moving average of $1.04. Aptose Biosciences has a 52 week low of $0.71 and a 52 week high of $3.13.

Analysts Set New Price Targets

APTO has been the subject of several recent research reports. Cantor Fitzgerald dropped their price target on shares of Aptose Biosciences from $10.00 to $6.00 in a research report on Wednesday, August 3rd. StockNews.com raised shares of Aptose Biosciences from a "sell" rating to a "hold" rating in a research note on Wednesday, May 18th.

Receive APTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APTO Stock News Headlines

Aptose Reports Results for the Second Quarter 2022
Aptose Biosciences (APTO) Set to Announce Earnings on Tuesday
Aptose names new CFO
Aptose Biosciences Appoints Fletcher Payne As CFO
Aptose Biosciences Q1 2022 Earnings Preview
Aptose Announces Executive Management Changes
Aptose Biosciences Q4 2021 Earnings Preview
Earnings Outlook For Aptose Biosciences
See More Headlines
Receive APTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APTO Company Calendar

Last Earnings
11/11/2021
Today
8/17/2022
Next Earnings (Estimated)
11/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APTO
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.67
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+914.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-65,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.60 per share

Miscellaneous

Free Float
82,188,000
Market Cap
$78.86 million
Optionable
Optionable
Beta
1.52














APTO Stock - Frequently Asked Questions

Should I buy or sell Aptose Biosciences stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" APTO shares.
View APTO analyst ratings
or view top-rated stocks.

What is Aptose Biosciences' stock price forecast for 2022?

3 Wall Street research analysts have issued 12-month target prices for Aptose Biosciences' stock. Their APTO share price forecasts range from $6.00 to $12.00. On average, they expect the company's share price to reach $8.67 in the next year. This suggests a possible upside of 914.1% from the stock's current price.
View analysts price targets for APTO
or view top-rated stocks among Wall Street analysts.

How have APTO shares performed in 2022?

Aptose Biosciences' stock was trading at $1.35 at the start of the year. Since then, APTO shares have decreased by 36.7% and is now trading at $0.8546.
View the best growth stocks for 2022 here
.

When is Aptose Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our APTO earnings forecast
.

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (NASDAQ:APTO) announced its quarterly earnings results on Thursday, November, 11th. The biotechnology company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.04. During the same quarter in the previous year, the company posted ($0.15) EPS.

What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO?

8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend.

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX).

What is Aptose Biosciences' stock symbol?

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

Who are Aptose Biosciences' major shareholders?

Aptose Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Nantahala Capital Management LLC (7.84%), Sanders Morris Harris LLC (1.11%), Sigma Planning Corp (0.91%), Voss Capital LLC (0.76%), Renaissance Technologies LLC (0.47%) and BNP Paribas Arbitrage SA (0.37%). Insiders that own company stock include Denis R Burger, Donald R Jr Wilson, Erich Platzer, Gregory K Chow, Jotin Marango, Rafael Bejar, Warren Whitehead and William G Rice.
View institutional ownership trends
.

How do I buy shares of Aptose Biosciences?

Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aptose Biosciences' stock price today?

One share of APTO stock can currently be purchased for approximately $0.85.

How much money does Aptose Biosciences make?

Aptose Biosciences (NASDAQ:APTO) has a market capitalization of $78.87 million. The biotechnology company earns $-65,350,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis.

How can I contact Aptose Biosciences?

Aptose Biosciences' mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The official website for the company is www.aptose.com. The biotechnology company can be reached via phone at 858-926-2730, via email at ir@aptose.com, or via fax at 905-234-2120.

This page (NASDAQ:APTO) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.